The epidemiology of cervical cancer

Cancer Journal

Volumn 9, Issue 5, 2003, Pages 348-359

  Franco, Eduardo L ^a,b   Schlecht, Nicolas F ^a,c   Saslow, Debbie ^a,d  

^a McGill University ^*

^b MCGILL UNIVERSITY   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

Author keywords

Cervical neoplasms; CIN; Epidemiology; Human papillomavirus; Pap test; Prevention; Screening

Indexed keywords

CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CAUSAL ATTRIBUTION; HOST SUSCEPTIBILITY; HUMAN; PARITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; SECONDARY PREVENTION; SEXUALLY TRANSMITTED DISEASE; SMOKING; UTERINE CERVIX CANCER; WART VIRUS; FEMALE; HEALTH; INCIDENCE; PAPILLOMA VIRUS; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; WORLD HEALTH;

EID: 1542754943     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200309000-00004     Document Type: Article

References (146)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al., SEER Cancer Statistics Review, 1975-2000. National Cancer Institute, 2003.
2. Cancer Facts and Figures. American Cancer Society, 2003.
3. CDC. Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993. MMWR Morb Mortal Wkly Rep 1994;43(29):530-534.
4. Wu XC, Holes JL, Fulton JP et al. Cancer in North America, 1995-1999. Volume 1: Incidence. North American Association of Central Cancer Registries (NAACCR), 2002.
5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Press, 2001.
6. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 (Suppl 8):S4-S66.
7. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54: 594-606.
8. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
9. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995; 75(1 Suppl):270-294.
10. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
11. Vizcaino AP, Moreno V, Bosch FX et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-545.
12. Parazzini F, La Vecchia C. Epidemiology of adenocarcinoma of the cervix. Gynecol Oncol 1990;39:40-46.
13. Ferenczy A. Glandular lesions: an increasing problem. In: Franco EL, Monsonego J, eds. New developments in cervical cancer screening and prevention. London: Blackwell, 1997:122-130.
14. Brinton LA. Epidemiology of cervical cancer-overview. IARC Sci Publ 1992(119)3-23.
15. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76(10 Suppl):1888-1901.
16. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996(21):1-6.
17. Schiffman MH, Brinton LA, Devesa SS, Fraumeni JFJ. Cervical Cancer. In: Schotenfled D, Fraumeni JFJ, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996: 1090-1116.
18. Franco EL. Viral etiology of cervical cancer: a critique of the evidence. Rev Infect Dis 1991;13:1195-1206.
19. Franco EL. The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology 1991; 2:98-106.
20. Munoz N, Bosch FX, de Sanjose S et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-749.
21. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327(18): 1272-1278.
22. Schiffman MH, Bauer HM, Hoover RN et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85: 958-964.
23. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698.
24. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
25. Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
26. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
27. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-511.
28. IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 64, International Agency for Research on Cancer, Lyon, 1995.
29. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
30. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
31. Cox JT. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus. Baillieres Clin Obstet Gynaecol 1995;9:1-37.
32. Hildesheim A, Schiffman MH, Gravitt PE et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-240.
33. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
34. Franco EL, Villa LL, Sobrinho JP et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.
35. Liaw KL, Hildesheim A, Burk RD et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.
36. Moscicki AB, Shiboski S, Broering J et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132: 277-284.
37. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354(9172):20-25.
38. Ylitalo N, Josefsson A, Melbye M et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000;60(21):6027-6032.
39. Schlecht NF, Kulaga S, Robitaille J et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286(24):3106-3114.
40. Moscicki AB, Hills N, Shiboski S et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285(23): 2995-3002.
41. Morrison EA, Ho GY, Vermund SH et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer 1991;49:6-13.
42. Bosch FX, Munoz N, de Sanjose S et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:415-422.
43. Lorincz AT, Castle PE, Sherman ME et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360(9328):228-229.
44. Schlecht NF, Trevisan A, Duarte-Franco E et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103:519-524.
45. Brisson J, Bairati I, Morin C et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996;173:794-749.
46. Swan DC, Tucker RA, Tortolero-Luna G et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-1034.
47. Xi LF, Koutsky LA, Galloway DA et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:796-802.
48. Hildesheim A, Schiffman M, Bromley C et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001;93:315-318.
49. Xi LF, Carter JJ, Galloway DA et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002;11:343-351.
50. Villa LL, Sichero L, Rahal P et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Viral 2000;81:2959-2968.
51. Berumen J, Ordonez RM, Lazcano E et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001;93(17):1325-1330.
52. Londesborough P, Ho L, Terry G et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-368.
53. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998;58:829-833.
54. Kammer C, Tommasino M, Syrjanen S et al. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer 2002;86:269-273.
55. Bontkes HJ, van Duin M, de Gruijl TD et al. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 1998;78:166-171.
56. Nindl I, Rindfleisch K, Lotz B et al. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 1999; 82:203-207.
57. Hu X, Guo Z, Tianyun P et al. HPV typing and HPV16 E6-sequence variations in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. Int J Cancer 1999;83: 34-37.
58. Brady CS, Duggan-Keen MF, Davidson JA et al. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol 1999; 80 (Pt 12):3233-3240.
59. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:886-891.
60. Nagao S, Yoshinouchi M, Miyagi Y et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J Clin Microbiol 2002;40: 863-867.
61. Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 2000;74:2679-2686.
62. Luft F, Klaes R, Nees M et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer 2001; 92:9-17.
63. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999;59(24): 6132-6136.
64. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002;3:11-16.
65. Schneider A, Holz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer 1987;40:198-201.
66. Pater MM, Mittal R, Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 1994;2:229-234.
67. Brinton LA, Hamman RF, Huggins GR et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987;79:23-30.
68. Brinton LA, Reeves WC, Brenes MM et al. Parity as a risk factor for cervical cancer. Am J Epidemiol 1989;130:486-496.
69. Munoz N, Franceschi S, Bosetti C et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;359(9312):1093-1101.
70. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89:191-199.
71. Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix uteri. A meta-analysis. Acta Obstet Gynecol Scand 1992;71:368-376.
72. Irwin KL, Rosero-Bixby L, Oberle MW et al. Oral contraceptives and cervical cancer risk in Costa Rica. Detection bias or causal association? JAMA 1988;259:59-64.
73. Moreno V, Bosch FX, Munoz N et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359(9312):1085-1092.
74. Smith JS, Green J, Berrington de Gonzalez A et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361(9364):1159- 1167.
75. Winkelstein W, Jr. Smoking and cervical cancer-current status: a review. Am J Epidemiol 1990;131:945-957; discussion 58-60.
76. de Vet HC, Sturmans F, Knipschild PG. The role of cigarette smoking in the etiology of cervical dysplasia. Epidemiology 1994; 5:631-633.
77. Brisson J, Morin C, Fortier M et al. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. Am J Epidemiol 1994;140:700-710.
78. Kjellberg L, Hallmans G, Ahren AM et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intraepithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-1338.
79. Olsen AO, Gjoen K, Sauer T et al. Human papillomavirus and cervical intraepithelial neoplasia grade II-III: a population-based case-control study. Int J Cancer 1995;61:312-315.
80. Sasagawa T, Dong Y, Saijoh K et al. Human papillomavirus infection and risk determinants for squamous intraepithelial lesion and cervical cancer in Japan. Jpn J Cancer Res 1997;88:376-384.
81. Schiff M, Becker TM, Masuk M et al. Risk factors for cervical intraepithelial neoplasia in southwestern American Indian women. Am J Epidemiol 2000;152:716-726.
82. Cuzick J, Singer A, De Stavola BL, Chomet J. Case-control study of risk factors for cervical intraepithelial neoplasia in young women. Eur J Cancer 1990;26:684-690.
83. Parazzini F, La Vecchia C, Negri E et al. Risk factors for cervical intraepithelial neoplasia. Cancer 1992;69:2276-2282.
84. Ho GY, Kadish AS, Burk RD et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78:281-285.
85. Castle PE, Wacholder S, Lorincz AT et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94(18):1406-1414.
86. Schiffman MH, Haley NJ, Fekon JS et al. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res 1987;47(14):3886-3888.
87. Palefsky JM, Holly EA. Molecular urology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:415-428.
88. Brock KE, Berry G, Mock PA et al. Nutrients in diet and plasma and risk of in situ cervical cancer. J Natl Cancer Inst 1988;80: 580-585.
89. VanEenwyk J, Davis F, Bowen P. Dietary and serum carotenoids and cervical intraepithelial neoplasia. Int J Cancer 1991;48: 34-38.
90. Van Eenwyk J, Davis F, Colman N. Folate, vitamin C, and cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1992;1:119-124.
91. Liu T, Soong SJ, Wilson NP et al. A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol Biomarkers Prev 1993;2:525-530.
92. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 1996;7:113-126.
93. Kwasniewska A, Charzewska J, Tukendorf A, Semczuk M. Dietary factors in women with dysplasia colli uteri associated with human papillomavirus infection. Nutr Cancer 1998;30:39-45.
94. Ziegler RG, Jones CJ, Brinton LA et al. Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Causes Control 1991;2:17-29.
95. de Vet HC, Knipschild PG, Grol ME et al. The role of beta-carotene and other dietary factors in the aetiology of cervical dysplasia: results of a case-control study. Int J Epidemiol 1991; 20:603-610.
96. Shannon J, Thomas DB, Ray RM et al. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control 2002;13:691-699.
97. Palan PR, Mikhail MS, Goldberg GL et al. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha- and tau-tocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res 1996;2:181-185.
98. Cuzick J, De Stavola BL, Russell MJ, Thomas BS. Vitamin A, vitamin E and the risk of cervical intraepithelial neoplasia. Br J Cancer 1990;62:651-652.
99. Kwasniewska A, Tukendorf A, Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 1997; 18:526-530.
100. Palan PR, Mikhail MS, Basu J, Romney SL. Plasma levels of antioxidant beta-carotene and alpha-tocopherol in uterine cervix dysplasias and cancer. Nutr Cancer 1991;15:13-20.
101. Goodman MT, McDuffie K, Hernandez B et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1275-1280.
102. Liu T, Soong SJ, Alvarez RD, Butterworth CE, Jr. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev 1995;4:373-380.
103. Giuliano AR. The role of nutrients in the prevention of cervical dysplasia and cancer. Nutrition 2000;16(7-8):570-573.
104. de Sanjose S, Munoz N, Bosch FX et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:358-363.
105. Koskela P, Anttila T, Bjorge T et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35-39.
106. Anttila T, Saikku P, Koskela P et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47-51.
107. Smith JS, Munoz N, Herrero R et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002;185:324-331.
108. Thomas DB, Qin Q, Kuypers J et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 2001;153:732-739.
109. Peng HQ, Liu SL, Mann V et al. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991; 47:711-716.
110. Ferrera A, Baay MF, Herbrink P et al. A sero-epidemiological study of the relationship between sexually transmitted agents and cervical cancer in Honduras. Int J Cancer 1997;73:781-785.
111. Lehtinen M, Koskela P, Jellum E et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol 2002;156:687-692.
112. Smith JES, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002;94(21):1604-1613.
113. Wright TCJ. Papillomavirus infection and neoplasia in women infected with human immunodeficiency virus. In: Franco EL, Monsonego J, eds. New developments in cervical cancer screening and prevention. Oxford: Blackwell Science, 1997:131-143.
114. Jay N, Moscicki AB. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. AIDS Read 2000;10:659-668.
115. Conley LJ, Ellerbrock TV, Bush TJ et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359(9301):108-113.
116. Langley CL, Benga-De E, Critchlow CW et al. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. AIDS 1996;10:413-417.
117. Rezza G, Giuliani M, Branca M et al. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group. Eur J Epidemiol 1997;13:937-943.
118. Maiman M, Fruchter RG, Sedlis A et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998;68:233-239.
119. Massad LS, Riester KA, Anastos KM et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999;21:33-41.
120. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-1037.
121. Moscicki AB, Ellenberg JH, Vermund SH et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000; 154:127-134.
122. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
123. Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999;8:97-106.
124. Minkoff H, Ahdieh L, Massad LS et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15(16):2157-2164.
125. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002;89:229-240.
126. Odunsi K, Terry G, Ho L et al. Association between HLA DQB1*03 and cervical intra-epithelial neoplasia. Mol Med 1995; 1:161-171.
127. Odunsi K, Terry G, Ho L et al. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996;67: 595-602.
128. Breitburd F, Ramoz N, Salmon J, Orth G. HLA control in the progression of human papillomavirus infections. Semin Cancer Biol 1996;7:359-371.
129. Hildesheim A, Schiffman M, Scott DR et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:1035-1041.
130. Odunsi KO, Ganesan TS. The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. Clin Oncol (R Coll Radiol) 1997;9:4-13.
131. Maciag PC, Schlecht NF, Souza PS et al. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000;9:1183-1191.
132. Apple RJ, Erlich HA, Klitz W et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-262.
133. Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 1995;87:427-436.
134. Sanjeevi CB, Hjelmstrom P, Hallmans G et al. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996;68:409-414.
135. Heiland A, Olsen AO, Gjoen K et al. An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women. Int J Cancer 1998;76:19-24.
136. Madeleine MM, Brumback B, Cushing-Haugen KL et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002;186:1565-1574.
137. Vales-Gomez M, Reybum H, Strominger J. Molecular analyses of the interactions between human NK receptors and their HLA ligands. Hum Immunol 2000;61:28-38.
138. Matlashewski GJ, Tuck S, Pim D et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-963.
139. Harris N, Brill E, Shohat O et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-4656.
140. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393(6682):229-234.
141. Makni H, Franco EL, Kaiano J et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000;87: 528-533.
142. Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003; 2003(31):89-96.
143. Miller AB, Nazeer S, Fonn S et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 2000; 86:440-447.
144. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21):1645-1651.
145. Weed DL. Causal and preventive inference. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer Prevention and Control New York: Marcel Dekker, 1995:285-302.
146. Hill A. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.